SP Investment Fund
VC Fund
Santa Monica, United States
SP Investment Fund is a VC fund in Santa Monica focused on Biotechnology and Health Care. SP Investment Fund LLC and its affiliated funds have invested in scores of technology and real estate companies
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
- Fund size:
- $697k
- Last fund:
Last updated:
For AI agents: llms.txt
Industries SP Investment Fund invests in
BiotechnologyHealth CareMedicalMedical DeviceHotel
Stages SP Investment Fund invests in
SeedSeries B
Countries SP Investment Fund invests in
United StatesFranceMexico
Round sizes
Seed $120k–$10M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $120k–$10M
Investment Focus
Industry
- Biotechnology 5 (45%)
- Health Care 4 (36%)
- Medical 3 (27%)
- Medical Device 3 (27%)
- Hotel 1 (9%)
Stage
- Seed 7 (64%)
- Series B 1 (9%)
Country
- United States 6 (55%)
- France 1 (9%)
- Mexico 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Gil Seton
Manager
|
Manager | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lattice Medical
|
Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $50M / Series B / Oct 24, 2025 | |
VenoStent
|
VenoStent is a clinical-stage tissue engineering company that’s developed tunable, bioabsorbable smart polymer wraps in order to fundamentally transform the 5 million vascular surgeries performed each year. | $3M / Seed / Feb 23, 2021 | |
Unima
|
Unima is decentralizing rapid testing across industries by taking diagnostics out of the lab to the place these are needed the most to secure a timely diagnostic for everyone, anywhere.Unima is solving is the centralization of lab testing, which limits the access to a timely diagnostic for billions. Current technology for diagnostics is veryprecise and can detect almost any disease known, but the problem is these require labs with expensive equipment and specialized technicians making lab testing impossible to scale up to provide universal and timely access to diagnostics.To solve this problem Unima developed Find, a rapid testing technology platform for real time diagnostics which allows anyone to diagnose a disease directly where it is needed, without using lab equipment, with results in 15 minutes or less and at a very low cost. With Find anyone can have access to a timely diagnostic even in the most remote areas of the world.The Find platform uses shark antibodies modified with genetic engineering to detect disease biomarkers in blood, saliva, urine or water samples. These shark antibodies are used in microfluidic cards and generate a visual reactions when in contact with specific biomarkers of the disease to be tested. Then to evaluate the result of the test, a picture of the testing card is taken with the proprietary Xplora smartphone app which runs image analysis process and neural network algorithms to generate an inmediate result. Then this result,along with contextual information like geolocation, date and time, is sent to a cloud server where it can be used for real time disease tracking. | $1.9M / Seed / Mar 24, 2019 | |
C16 Biosciences
|
C16 Biosciences is a biotechnology firm that uses microbiology to brew sustainable alternatives to palm oil.Utilizing its exclusive platform, the company is generating innovative ingredients without concessions for top global consumer goods manufacturers. Recently, they introduced the Palmless™ platform for sustainable ingredients, along withtheir inaugural biodesigned ingredient, Torula oil—a premium bioactive oil with clinically proven benefits for enhancing skin and hair health. | Seed / Aug 28, 2018 | |
|
C16 Biosciences
|
C16 Biosciences is a biotechnology firm that uses microbiology to brew sustainable alternatives to palm oil.Utilizing its exclusive platform, the company is generating innovative ingredients without concessions for top global consumer goods manufacturers. Recently, they introduced the Palmless™ platform for sustainable ingredients, along withtheir inaugural biodesigned ingredient, Torula oil—a premium bioactive oil with clinically proven benefits for enhancing skin and hair health. | $4M / Seed / Aug 20, 2018 | |
HepaTx
|
HepaTx is developing regenerative medicine solutions to address the need for better therapies for life-threatening liver diseases. The technology invented at Stanford University enables efficient hepatocyte production for therapeutic purposes. Its therapeutics can replace lost liver function to treat those with end-stage of liver disease,potentially saving the cost and morbidity of whole organ transplant. | $2.1M / Seed / Aug 20, 2018 | |
Allotrope Medical
|
Allotrope Medical is a Houston-based medical device company. Allotrope Medical’s first device, the StimSite, is an intuitive hand-held device that assists surgeons in quickly and easily identifying ureters during a surgical procedure. | $120K / Seed / Aug 20, 2018 | |
Opentrons
|
OpenTrons is a developer of a pipetting robot technology designed to automate experiments. The company's technology is automated laboratory equipment that automates experiments by using Python language, enabling scientific researchers to make the process faster and less tiresome. | $10M / Seed / Mar 27, 2018 | |
|
Unima
|
Unima is decentralizing rapid testing across industries by taking diagnostics out of the lab to the place these are needed the most to secure a timely diagnostic for everyone, anywhere.Unima is solving is the centralization of lab testing, which limits the access to a timely diagnostic for billions. Current technology for diagnostics is veryprecise and can detect almost any disease known, but the problem is these require labs with expensive equipment and specialized technicians making lab testing impossible to scale up to provide universal and timely access to diagnostics.To solve this problem Unima developed Find, a rapid testing technology platform for real time diagnostics which allows anyone to diagnose a disease directly where it is needed, without using lab equipment, with results in 15 minutes or less and at a very low cost. With Find anyone can have access to a timely diagnostic even in the most remote areas of the world.The Find platform uses shark antibodies modified with genetic engineering to detect disease biomarkers in blood, saliva, urine or water samples. These shark antibodies are used in microfluidic cards and generate a visual reactions when in contact with specific biomarkers of the disease to be tested. Then to evaluate the result of the test, a picture of the testing card is taken with the proprietary Xplora smartphone app which runs image analysis process and neural network algorithms to generate an inmediate result. Then this result,along with contextual information like geolocation, date and time, is sent to a cloud server where it can be used for real time disease tracking. | $1.6M / Seed / Mar 24, 2016 | |
Roomstorm
|
Roomstorm (Formerly WalkSource) is a next generation Business-to-Business network for hoteliers looking to run operations more efficiently and generate more revenue. Roomstorm empowers revenue teams to have more sellout nights by taking in last minute guest relocations from other nearby hotels as well as airlines in need of housing guestsovernight. Roomstorm proudly services over 400 Bay Area hotels and continues to grow with the recent edition of our first airline partner, San Francisco based Virgin America. Our hotel partners confidently overbook their properties, exchange lower priced guests for higher priced ones, find good deals for a relocated guest end-to-end within 5 minutes. By eliminating the pain of dealing with a relocations, we make the market much more efficient. | $1.3M / Seed / May 05, 2015 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
47,147 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
Medical Investors
20,530 investors
Medical Device Investors
12,078 investors
Health Care VC Funds
35,356 investors
Biotech VC Funds
20,362 investors
Biotechnology VC Funds
18,327 investors
Medical VC Funds
17,653 investors
FAQ
What does SP Investment Fund invest in?
SP Investment Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SP Investment Fund's check size?
SP Investment Fund typically joins rounds of $120k–$10M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SP Investment Fund participates in.
How do I contact SP Investment Fund?
Public channels for SP Investment Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SP Investment Fund?
The team at SP Investment Fund includes Gil Seton (Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
